Alkermes wins FDA nod for combo med with antipsychotic olanzapine — this time without the weight gain red flags
Alkermes has had a rough go in the past few years, making the decision to slice away a healthy portion of its R&D workforce last year after a major setback in depression. The drugmaker placed a lot of hope in antipsychotic drug ALKS 3831 to turn things around, and after a winning adcomm late last year that bet is finally paying off.
The FDA on Tuesday approved Alkermes’ Lybalvi (olanzapine and samidorphan) to treat schizophrenia and bipolar 1 disorder, the company said in a release.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.